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ABSTRACT
Background There is less data available regarding the
characteristics of cognitive impairment in patients with
amyotrophic lateral sclerosis (ALS) in a population-based
series.
Methodology Patients with ALS incident in Piemonte,
Italy, between 2009 and 2011 underwent an extensive
neuropsychological battery. Cognitive status was
classiﬁed as follows: normal cognition, frontotemporal
dementia (ALS-FTD), executive cognitive impairment
(ALS-ECI), non-executive cognitive impairment
(ALS-NECI), behavioural impairment (ALS-Bi), non-
classiﬁable cognitive impairment. We also assessed 127
age-matched and gender-matched controls identiﬁed
through patients’ general practitioners.
Results Out of the 281 incident patients, 207 (71.9%)
underwent the neuropsychological testing; of these, 19
were excluded from the analysis due previous conditions
affecting cognition. Ninety-one (49.7%) patients were
cognitively normal, 23 (12.6%) had ALS-FTD, 36
(19.7%) ALS-ECI, 10 (5.5%) ALS-NECI, 11 (6.0%)
ALS-Bi and 11 (6.0%) non-classiﬁable cognitive
impairment, 1 had comorbid Alzheimer’s disease.
Patients with ALS-FTD were older, had a lower education
level, and had a shorter survival than any other cognitive
group. Of the nine cases with C9ORF72 mutation,
six had ALS-FTD, two ALS-ECI and one was cognitively
normal; one of the ﬁve patients with SOD1 mutations
and one of the ﬁve patients with TARBDP mutations had
ALS-Bi.
Conclusions About 50% of Italian patients with ALS
had some degree of cognitive impairment, in keeping with
a previous Irish study, despite the largely different genetic
background of the two populations. The lower educational
attainment in patients with ALS-FTD indicated a possible
role of cognitive reserve in ALS-related cognitive
impairment. ALS-ECI and ALS-NECI may represent discrete
cognitive syndromes in the continuum of ALS and FTD.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurode-
generative disease characterised by a progressive
loss of spinal, bulbar and cortical motor neurons,
leading to voluntary muscles weakness and wasting
and ultimately to death due to respiratory failure.
While in about 90% of patients ALS occurs sporad-
ically, in 10% it is genetically transmitted.1 2
Extramotor features in ALS include cognitive
changes, which have been described in 10–50% of
patients.3 4
Frequency and clinical correlates of cognitive
impairment in ALS are still poorly understood.
With only one exception,4 all studies have been
performed on small clinic-based cohorts and did
not use standardised methodologies for the evalu-
ation of cognition. Recent consensus criteria pro-
posed a classiﬁcation of frontotemporal cognitive
and behavioural syndromes in ALS5 which includes
ALS with frontotemporal dementia (ALS-FTD) and
two milder forms of ALS with behavioural impair-
ment (ALS-Bi) and ALS with cognitive impairment.
The aim of this study was to assess the frequency
and the clinical pattern of cognitive impairment in
a population-based series of patients with ALS,
identiﬁed through the Piemonte and Valle d’Aosta
register for ALS (PARALS), fully characterised from
the clinical and genetic point of view.
METHODS
We invited to participate to the study all patients
with ALS resident in the provinces of Torino and
Cuneo of Piemonte region, Italy, (n=281), and
diagnosed between 1 January 2009 and 31
December 2011, identiﬁed through the Piemonte
and Valle d’Aosta register for ALS,6 meeting El
Escorial revised diagnostic criteria for deﬁnite,
probable and probable laboratory-supported ALS.7
Disease severity was assessed with the amyotrophic
lateral sclerosis—functional rating scale revised
(ALSFRS-R) scale.8 All patients underwent pulmon-
ary function tests within 4 weeks before or after
the neuropsychological evaluation.
Patients with history of neurological disorders
affecting cognition (major stroke, severe head injur-
ies, mental retardation), alcohol-dependence and
drug-dependence, severe mental illness and use of
high-dose psychoactive medications were tested but
not included in data analysis. Patients resident in
the area but who were not of Italian mother tongue
were assessed only through an unstructured inter-
view and therefore were excluded from the ana-
lysis. Patients were invited to participate to the
study at the time of the diagnosis or during the ﬁrst
scheduled follow-up visit (∼2 months later) and
were interviewed at home or at the ALS clinic. In
no case cognitive examination was performed more
than 12 months after diagnosis. A total of 127
healthy age-matched, gender-matched and
education-matched controls underwent the same
neuropsychological battery. Controls were enrolled
thought patients’ general practitioners (GPs) and
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were interviewed at home, at the GP ofﬁce or at the hospital.
Only nine subjects asked to participate as controls denied their
participation. Most GPs were willing to collaborate (∼85%).
When a GP did not collaborate, another GP practicing in the
same area was contacted.
Neuropsychological battery
Patients and controls underwent a battery of neuropsychological
tests encompassing executive function, memory, visuospatial
function and language, selected according to Clinical Diagnostic
Criteria for Frontotemporal Lobar Degeneration,9 and
ALS-FTD Consensus Criteria.5 The neuropsychological battery
included: Mini Mental State Examination; Wisconsin Card
Sorting Test; Trail Making A and B; Stroop Colour-Word
Interference Test; letter and category ﬂuency test; Wechsler
Memory Scale II—revised (Form 2); Rey-Osterrieth Complex
Figure Test; Token test; Wechsler Adult Intelligence Scale
revised; Raven’s Progressive Colored Matrices; Frontal
Assessment Battery. In some cases supplementary tasks were
administered for a comprehensive evaluation of language; the
following tests were used: semantic systems tests (7 and 8) of
the Battery for the Analysis of Aphasic Deﬁcits10 and the
Silhouette trial of the Visual Object and Space Perception
battery.11
Neurobehavioral dysfunction was determined on the basis of
direct observation and patient’s history,9 12 and with the Frontal
Systems Behavior Scale,13 using the Family-form evaluated by a
close relative (scores: normal ≤59, borderline 60–64; patho-
logical ≥65). If a subject had scores reﬂecting a frontal systems
abnormality in the premorbid and in the postillness forms, he/
she was considered pathological only if there was an increase of
≥10 points at the T score between the two forms.14 Anxiety and
depression were assessed with the Hospital Anxiety and
Depression Scale; the item ‘I feel slowed down’ was discussed
with patients in order not to refer to physical disability.
Cognitive impairment was deﬁned as impairment on two tests
of executive or non-executive function that was below the 5th
centile of healthy controls.
The battery was administered following the same sequence in
order to avoid the possible differential interference of the
answers of one test over the others. The administration of
the battery required ∼2 h, and was usually performed in the
morning. If the subject felt too tired, a further session was
scheduled to complete the battery, within 2 weeks after the ﬁrst
one. Patients’ and controls’ O2 saturation at the time of the
neuropsychological testing was measured with a pulse oximetry;
none of the patients and controls had evidence of hypoxaemia
(oxygen saturation <92 mm Hg).
Cognitive classiﬁcation
Clinical diagnosis and cognitive classiﬁcation were performed
with the collaboration of two neurologists specialist in ALS and
FTD and two neuropsychologists. Patients’ cognitive status was
classiﬁed as follows:
A. ALS with normal cognition.
B. ALS with frontotemporal dementia (ALS-FTD). The diagno-
sis of frontotemporal dementia was deﬁned according to
Clinical Diagnostic Criteria for Frontotemporal Lobar
Degeneration.9
C. ALS comorbid with non-FTD dementias. The diagnoses of
non-FTD dementias were based on the criteria of the
Diagnostic and Statistical Manual of Mental
Disorders-IV-TR15 and those of the National Institute of
Neurological and Communicative Disorders and Stroke—
Alzheimer’s Disease and Related Disorders Association.16
D. ALS with executive cognitive impairment (ALS-ECI). Patients
with ALS who did not meet criteria for FTD or other types
of dementia, but who had an impairment in two tests of
executive dysfunction compared with healthy controls, that
is, had an executive dysfunction, were classiﬁed as ALS with
executive cognitive dysfunction. A more conservative cut-off
than that proposed by the ALS-FTD Consensus Criteria5
was used (2.3rd centile).4
E. ALS with non-executive cognitive impairment (ALS-NECI).
This group includes patients with ALS with impairment in
two non-executive domains, in particular visuopraxic abil-
ities, and no impairment in executive function.
F. ALS with behavioural impairment (ALS-Bi). This group
includes patients with predominant behavioural disturbances
and with impairment in none or only one test of executive
dysfunction and no impairment in non-executive domains.
G. ALS with non-classiﬁable cognitive impairment (ALS-NCCI).
This group includes patients with ALS with impairment in
one executive and/or one non-executive test, sometimes
associated with smooth behavioural changes.
Genetic analysis
All coding exons and 50 bp of the ﬂanking intron-exon bound-
aries of SOD1, of exon 6 of TARDBP, and of exons 14 and 15
of FUS and exons 5, 9, 12 and 14 of OPTN and the single exon
of ANG have been PCR ampliﬁed, sequenced using the Big-Dye
Terminator v3.1 sequencing kit (Applied Biosystems), and run
on an ABIPrism 3130 genetic analyser. In patients with positive
family history for ALS or FTD all coding exons of VCP have
also been assessed. These exons were selected as the vast major-
ity of known pathogenic variants are known to lie within these
mutational hot spots. A repeat-primed PCR assay was used to
screen for the presence of the GGGGCC hexanucleotide expan-
sion in the ﬁrst intron of C9ORF72.17 A cut-off of ≥30 repeats
was considered pathological.
Statistical methods
Comparisons between means were made with Student t test or
analysis of variance; comparisons between categorical variables
were made with χ2 test; for all comparisons, Levene’s test was
used to conﬁrm the equality of variances.
Survival was calculated from onset to death/tracheostomy or
censoring date (30 June 2013), using the Kaplan-Meier method,
and compared with the log-rank test. No patients were lost to
follow-up. Multivariable analysis was performed with Cox pro-
portional hazards model (stepwise backward) (for details, see
table 3). For the analysis of the relationship between cognitive
status and disease progression, the progression rate for the
ALSFRS-R score, its four subscores (bulbar, ﬁne motor, gross
motor and respiratory) and forced vital capacity per cent of pre-
dicted (FVC%) was calculated as the mean monthly number of
points lost from disease onset to the time of cognitive evalu-
ation. For example, the progression rate for the ALSFRS-R
score was calculated as follows: (48-ALSFRS-R at time of cogni-
tive evaluation)/duration from onset to diagnosis (months). In
the Cox model, these variables were dichotomised on the basis
of their median value. The list of all variables included in the
Cox model is reported in table 3.
A p level <0.05 was considered statistically signiﬁcant. All
tests were two-tailed. Statistical analyses were carried out using
SPSS V.20.0 (SPSS, Chicago, Illinois, USA).
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Standard protocol approvals, registrations and patient
consents
The study design was approved by our institutional Ethical
Committee. Patients and controls signed a written informed
consent. The database was managed according to the Italian law
for the protection of privacy.
RESULTS
A ﬂow chart of the sequence of participants’ selection is
reported in ﬁgure 1. Of the 281 patients diagnosed in the study
area in the 2009–2011 period, 202 (71.9%) underwent the
neuropsychological battery. Of the 79 non-captured patients, 34
were not able to undergo the battery of tests due to their motor
disability (7 patients were tracheostomised or used non-invasive
ventilation for more than 16 h; 18 patients had severe difﬁcul-
ties in writing and speaking; 9 patients had a severe fatigue and,
although willing to collaborate, could not adequately perform
the whole battery), 5 were not of Italian mother tongue, 30
declined participation and 10 died before being tested.
Nineteen tested patients were excluded from the analysis due to
previous neurological disorders affecting cognition (seven
patients), severe mental illness (six), drug or alcohol abuse
(two), use of high-dose psychoactive medications (one due to
bipolar disorder, one due to paranoid schizophrenia), analpha-
betism (one) and mental retardation (one).
Non-captured patients did not differ demographically and
clinically from those who underwent the examination (table 1).
The median time from diagnosis to the neuropsychological
assessment was 1.9 months (IQR 1.2–3.8 months).
Cognitive classiﬁcation
According to the classiﬁcation criteria for patients’ cognitive
status, 23 (12.6%) had ALS-FTD, 36 (19.7%) ALS-ECI, 10
(5.5%) ALS-NECI, 11 (6.0%) ALS-Bi and 11 (6.0%) ALS-NCCI;
91 (49.7%) patients were cognitively normal (see online
E-ﬁgure S1). One patient had comorbid Alzheimer disease (AD).
Twenty-two out of the 23 patients with ALS-FTD presented with
behavioural changes typical of behavioural variant fronto-temporal
lobar dementia (FTLD); one patient had semantic dementia.
Mean scores of the performed tests for each cognitive group and
controls are reported in online E-table 1. Box plots of selected test
are reported in online E- ﬁgures S2–S6.
Cognitive groups were clinically and demographically different
(table 2). Patients with ALS-FTD, ALS-ECI and ALS-Bi had a
higher mean age (∼70 years) than those with normal cognition
and ALS-NECI. ALS-NCCI had the lowest age at onset. Patients
with ALS-FTD and those with ALS-NECI had a higher frequency
of bulbar onset than all other groups (p=0.003). The mean
number of education years was signiﬁcantly lower in patients
with ALS-FTD than in all other groups. ALSFRS-R score and
FVC% at the time of the cognitive examination did not show sig-
niﬁcant differences. However, the ALSFRS-R bulbar subscore
(items 1, 2 and 3 of the ALSFRS-R scale) was signiﬁcantly lower
in the group with ALS-FTD (data not shown). The rate of decline
of ALSFRS-R, of its subscores and of FVC% was similar in the
various groups (see online E-table S2).
Patients’ cognitive status and genetics
Of the nine cases carrying the GGGGCC hexanucleotide repeat
expansion in the ﬁrst intron of the C9ORF72 gene, six had
ALS-FTD, two ALS-ECI and one was cognitively normal. One
of the ﬁve patients with SOD1 mutations and one of the ﬁve
patients with TARBDP mutation had ALS-Bi. Both patients with
FUS and OPTN mutations were cognitively normal. Genetic
status was signiﬁcantly correlated to the presence/absence of
cognitive impairment (p=0.0001).
Survival analysis
The overall median survival time was 2.7 years (95% CI 2.4 to
2.9) (ﬁgure 2). Patients with ALS-FTD had a signiﬁcantly
shorter survival (1.9 years, 95% CI 1.7 to 2.2) than any other
group of patients with cognitive impairment, with the only
exception of those with ALS-NECI (2.0 years, 95% CI 1.6 to
2.4). Patients with ALS-Bi (3.0 years, 95% CI 0.8 to 5.3) had a
survival time similar to that of cognitively normal patients (3.1
years, 95% CI 2.7 to 3.4). Patients with ALS-ECI had an inter-
mediate survival between the two groups (2.6 years, 95% CI
2.0 to 3.1). Cognitive status remained signiﬁcant in Cox multi-
variable analysis (table 3). The presence of FTD signiﬁcantly
increased the risk of death compared with non-demented
patients; also ALS-NECI and ALS-ECI resulted to be independ-
ently related to a worse outcome.
Figure 1 Flow chart showing capture
rate and the sequence of participant
selection. ALS, amyotrophic lateral
sclerosis.
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DISCUSSION
We have studied cognitive status in a population-based series of
patients with ALS in Italy using an extensive battery of tests
evaluating multiple cognitive domains. In our series, 13% of
patients had a comorbid FTD, while 50% had normal cogni-
tion. The remaining patients who did not meet the criteria for
FTD, but otherwise had some clinical signiﬁcance, including a
negative effect on disease outcome, showed various degrees of
cognitive impairment.
The frequency of cognitive impairment in our epidemio-
logical series was similar to that described in Irish patients.4
However, differently from that study, according to ALS-FTD
Consensus Criteria5 we identiﬁed a group of patients with cog-
nitive impairment, that is, patients with isolated behavioural
impairment, accounting for 6% of cases. These patients did not
show impairment in more than one executive or one non-
executive test, but had a behavioural impairment at extensive
clinical observation and at the Frontal Systems Behavior Scale
test. Interestingly, one control patient also met the criteria for
cognitive behavioural impairment.
We also identiﬁed a group of patients (6% of our series)
(NCCI) with impairment in one executive and/or one non-
executive test who did not fulﬁll the criteria for other cogni-
tive groups. These patients largely differed from cognitively
normal patients and from all other cognitive subgroups, being
younger, less frequently bulbar, and with a higher mean
education level. It is possible that this group includes premor-
bid FTD cases, that is, patients who did not meet the criteria
for other cognitive impairments but who could have devel-
oped more severe impairment later in the course of the
disease.
In our series, patients with ALS-FTD with full-blown
comorbid dementia had a signiﬁcantly lower educational level,
in keeping with another population-based study.4 The lower
mean educational level in Italian patients and controls in this
series compared with that of the Irish study4 reﬂects the low
level of education in the Italian population born before 1950.18
Educational level, as well as higher occupation attainment, are
considered proxies of cognitive reserve.19 The role of cognitive
reserve in protecting from AD is widely accepted,19 although
the underlying mechanisms are still unclear. Cognitive reserve is
also involved as a protective mechanism in several cognitive
functions impaired in FTD, in particular speed of processing/
executive functioning, visual spatial abilities and verbal
memory.20–22 Our ﬁnding suggests that either a long-standing
frontal dysfunction interferes with learning and might underline
the future development of cognitive impairment or low educa-
tion level puts patients at higher risk of developing FTD.
Differently from patients with ALS-FTD, those with ALS-ECI,
ALS-NECI and ALS-Bi did not differ from normal controls
regarding educational level, and those with ALS-NCCI had a
higher educational level than other cognitive groups and con-
trols. This ﬁnding may indicate that either cognitive reserve
does not have a role in these variants of cognitive impairments
in ALS, or that some patients develop cognitive impairment not
meeting the full criteria for FTD because they are protected by
their cognitive reserve.
Patients with ALS-FTD and ALS-ECI had an older age at
onset than controls, ALS-Bi and ALS-NECI, in keeping with
various papers,3 23 but not all.4 24 This difference may be due
to the higher mean age of our patients compared with other
series.4 24
In our series, bulbar onset was signiﬁcantly more frequent in
ALS-FTD and ALS-NECI. Bulbar onset has been found to be
more commonly related to FTD features in several series,3 25 26
but not in all.4 23 Supporting our ﬁndings, a [18F]2-ﬂuoro-2-
deoxy-D-glucose (FDG) Positron Emission Tomography (FDG-
PET) study showed a signiﬁcantly higher relative decrease in
metabolism in large frontal and parietal regions in bulbar onset
patients compared with spinal ones.27
Table 1 Demographic and clinical characteristics of patients with
ALS and controls
Patients with ALS
enrolled for the
study (n=183)*
Non-captured
patients with
ALS (n=79)
Healthy
controls
(n=127)
Mean age at onset
(years, SD)
67.0 (9.9) 66.9 (10.3) 66.5 (11.4)
Gender (female, %) 76 (41.5%) 35 (44.3%) 54 (42.5%)
Education (number
of years, SD)
8.3 (4.1) 8.5 (4.2) 8.7 (4.3)
Site of onset
(bulbar, %)
62 (33.9%) 26 (32.9%) –
All comparisons are non-significant.
*Nineteen patients tested but not included in the study due to exclusion criteria (see
text) are not shown in the table.
ALS, amyotrophic lateral sclerosis.
Table 2 Demographic and clinical characteristics of patients with ALS according to cognitive status
Cognitively normal
(n=91)
ALS-FTD
(n=23)
ALS-ECI
(n=36)
ALS-NECI
(n=10)
ALS-Bi
(n=11)
ALS-NCCI
(n=11) p Value
Mean age at onset (years, SD) 65.9 (10.6) 69.1 (7.7) 70.0 (7.4) 64.9 (12.8) 68.1 (9.9) 61.9 (9.5) 0.04
Gender (female, %) 40 (43.5%) 11 (47.8%) 14 (38.9%) 4 (40.0%) 4 (36.8%) 4 (36.8%) 0.97
Disease duration at time of interview (years, SD) 1.23 (1.11) 1.28 (0.60) 1.18 (0.76) 1.03 (0.63) 1.19 (1.17) 1.20 (0.62) 0.99
Site of onset (bulbar, %) 28 (30.4%) 10 (60.9%) 10 (27.8%) 6 (60.0%) 2 (18.2%) 2 (18.2%) 0.015
Time lapse between diagnosis and interview (years, SD) 0.25 (0.23) 0.35 (0.31) 0.26 (0.26) 0.12 (0.05) 0.18 (0.12) 0.31 (0.32) 0.12
Mean education (years, SD) 8.6 (3.7) 4.7 (1.9) 7.8 (4.0) 9.5 (5.1) 9.9 (5.2) 12.4 (4.4) 0.0001
FALS (%) 11 (12.1%) 7 (30.4%) 2 (5.6%) 0 0 0 0.015
Mean ALSFRS-R score at time of interview (SD) 38.8 (7.6) 34.9 (7.3) 36.4 (7.6) 40.9 (6.4) 34.5 (12.8) 39.7 (6.3) 0.086
Mean FVC% at time of interview (SD) 91.2 (25.5) 80.7 (25.0) 88.4 (28.7) 83.2 (22.3) 83.7 (26.6) 92.3 (23.1) 0.181
One patient with comorbid Alzheimer’s disease is not included in the table.
p Value is calculated with analysis of variance (age, education, time lapse, ALSFRS-R, FVC) or χ2 (gender, site of onset, FALS status).
ALS, amyotrophic lateral sclerosis; Bi, behavioural impairment; ECI, executive cognitive impairment; FALS, familial ALS; FTD, frontotemporal dementia; FVC%, forced vital capacity per
cent of predicted; NECI, non-executive cognitive impairment; NCCI, non-classifiable cognitive impairment.
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In this study a genetic characterisation of all patients with
ALS was performed. C9ORF72 hexanucleotide repeat expan-
sion was the more frequent mutation, and, as expected,1 28 it
was also the one signiﬁcantly associated with FTD compared
with other gene mutations or no genetic mutations. However,
patients with FTD with C9ORF72 mutation accounted only for
a fourth of all cases with ALS-FTD, indicating that other
genetic, epigenetic or environmental mechanisms underlie the
involvement of prefrontal cortex in ALS. The role of still
unknown genes is supported by the fact that ALS-FTD was
more commonly related to a positive family history of ALS than
all other cognitive conditions.
Cognitive impairment has a strong negative impact on ALS
outcome.4 14 26 29 30 The survival of our patients with
ALS-FTD and ALS-ECI was about 1 year shorter than that of
cognitively normal, patients with ALS-Bi and ALS-NECI. The
reason of this ﬁnding is still not completely understood. The
presence of neurobehavioral dysfunction or of isolate dysexecu-
tive behaviour in ALS at diagnosis has been found to be a strong
predictor of a poor outcome, partially related to a reduced efﬁ-
cacy of life-prolonging therapies such as non-invasive ventilation
and percutaneous endoscopic gastrostomy,14 while the decline
in cognitive function was faster in patients who were cognitively
impaired at baseline.31 However, we could not ﬁnd any signiﬁ-
cant correlation between ALS progression, evaluated with
ALSFRS-R at the time of the interview, and patients’ cognitive
status, indicating that the shorter survival of patients with ALS
with cognitive impairment is not completely explained by the
progression rate of their motor impairment. Cox multivariable
analysis conﬁrmed that cognitive status was independently
related to ALS outcome.
A limitation of this study is that it is based on a single obser-
vation shortly after the diagnosis of the disease. However, at
least two series with a follow-up cognitive assessment in patients
with ALS found that an onset of FTD or other forms of cogni-
tive impairment is rare during the disease course.31 32
In this study of cognitive status of incident Italian patients
with ALS, the frequency of cognitive impairment was similar to
that reported by a population-based study performed in
Ireland,4 despite the different genetic backgrounds of the two
populations,1 2 that is, the higher frequency of C9ORF72 muta-
tions in Ireland, and of SOD1 and TARDBP mutations in Italy.
We found that ∼15% of patients had ALS-FTD and another
35% had some degree of cognitive impairment. Comorbid FTD
was associated with higher age at onset, bulbar onset and lower
educational level, likely to represent a proxy for a reduced cog-
nitive reserve, and has a signiﬁcantly reduced survival than any
other cognitive group. It remains to be understood whether
ALS-ECI and ALS-NECI represent incomplete forms of cogni-
tive impairment or discrete cognitive syndromes within the
spectrum of ALS and FTD, with strong effect on the disease
outcome.
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Figure 2 Survival curves from disease onset to death/tracheostomy of
the incident amyotrophic lateral sclerosis (ALS) cohort according to
their cognitive classiﬁcation; p=0.004. Ticks are censored patients. Red,
patients with ALS with normal cognition; green, patients with ALS with
comorbid frontotemporal dementia (ALS-FTD); yellow, patients with
ALS with executive cognitive impairment (ALS-ECI); violet, patients with
ALS with non-executive cognitive impairment (ALS-NECI); blue, patients
with ALS with behavioural impairment (ALS-Bi); black, patients with
ALS with non-classiﬁable cognitive impairment (ALS-NCCI). The single
patient with ALS with comorbid dementia of Alzheimer’s type is not
included.
Table 3 Cox’s multivariable analysis
Variable OR (95% CI) p Value
ALS-FTD No
Yes
1
3.7 (2.1 to 6.6)
0.0001
ALSFRS total score <0.7 points/month
≥0.7 points/month
1
1.9 (1.3 to 2.9)
0.003
ALS-NECI No
Yes
1
3.6 (1.5 to 8.7)
0.004
ALS-ECI No
Yes
1
1.8 (1.1 to 3.1)
0.025
Type of onset Spinal
Bulbar
1
1.7 (1.1 to 2.7)
0.03
The following variables were included in the Cox model: age (18–59, 60–69, 70–79,
80–99) years, gender, FALS status (FALS vs SALS), gene mutation (C9ORF72, SOD1,
TARDBP, FUS, OPTN, no mutation identified), years of education (≤5, 6–8, 9–13,
≥14), progression rate of ALSFRS-R total score (<0.7 vs ≥0.7 point/months),
ALSFRS-R bulbar score (<0.15 vs ≥0.15 points/month), ALSFRS-R fine motor score
(<0.2 vs ≥0.2 points/month), ALSFRS-R gross motor score (<0.22 vs ≥0.22 points/
month), ALSFRS-R respiratory score (<0.1 vs ≥0.1 points/month), FVC% (<0.50 vs
≥0.50 months). Cognitive status was included as ALS-FTD (yes vs no), ALS-ECI (yes vs
no), ALS-NECI (yes vs no) ALS-Bi (yes vs no) and ALS-NCCI (yes vs no). Enteral
nutrition and non-invasive ventilation were included as time-dependent variables.
ALS, amyotrophic lateral sclerosis; Bi, behavioural impairment; ECI, executive
cognitive impairment; FALS, familial ALS; FTD, frontotemporal dementia; FVC%,
forced vital capacity per cent of predicted; NECI, non-executive cognitive impairment;
NCCI, non-classifiable cognitive impairment.
Montuschi A, et al. J Neurol Neurosurg Psychiatry 2014;0:1–6. doi:10.1136/jnnp-2013-307223 5
Neurodegeneration
 group.bmj.com on September 24, 2014 - Published by jnnp.bmj.comDownloaded from 
Regione Piemonte (Ricerca Finalizzata), University of Torino, Federazione Italiana
Giuoco Calcio, Fondazione Vialli e Mauro onlus, and European Commission (Health
Seventh Framework Programme); he serves on scientiﬁc advisory boards for Biogen
Idec and Cytokinetics.
Patient consent Obtained.
Ethics approval Comitato Etico Ospedale San Giovanni Battista di Torino.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1 Chiò A, Calvo A, Mazzini L, et al. Extensive genetics of ALS: a population-based
study in Italy. Neurology 2012;79:1983–9.
2 Kenna KP, McLaughlin RL, Byrne S, et al. Delineating the genetic heterogeneity of
ALS using targeted high-throughput sequencing. J Med Genet 2013;50:776–83.
3 Lomen-Hoerth C, Murphy J, Langmore S, et al. Are amyotrophic lateral sclerosis
patients cognitively normal? Neurology 2003;60:1094–7.
4 Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in
amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg
Psychiatry 2011;83:102–8.
5 Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of
frontotemporal cognitive and behavioral syndromes in amyotrophic lateral sclerosis.
Amyotroph Lateral Scler 2009;10:131–46.
6 Chiò A, Mora G, Calvo A, et al. Epidemiology of ALS in Italy: a 10-year prospective
population-based study. Neurology 2009;72:725–31.
7 Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the
diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor
Neuron Disord 2000;1:293–9.
8 Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional
rating scale that incorporates assessments of respiratory function. BDNF ALS Study
Group (Phase III). J Neurol Sci 1999;169:13–21.
9 Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration:
a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–54.
10 Miceli G, Laudanna A, Burani C, et al. Batteria per l’Analisi dei Deﬁcit Afasici B.A.
D.A., Roma, CEPSAG, Università Cattolica del Sacro Cuore, 1994.
11 Warrington EK, James M. The Visual Object and Space Perception Battery (VOSP).
Bury St. Edmunds, England: Thames Valley Test Co, 1991.
12 Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic
criteria for the behavioural variant of frontotemporal dementia. Brain
2011;134:2456–77.
13 Grace J, Malloy P. Frontal Systems Behavior Scale (FrSBe): Professional Manual.
Lutz, Fla, Psychological Assessment Resources, 2001.
14 Chiò A, Ilardi A, Cammarosano S, et al. Neurobehavioral dysfunction in ALS has a
negative effect on outcome and use of PEG and NIV. Neurology 2012;78:1085–9.
15 American Psychiatric Association. Diagnostic and statistical manual of mental
disorders. 4th edn. text rev. American Psychiatric Press, Washington, DC, 2000.
16 McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s
disease: report of the NINCDS-ADRDA Work Group under the auspices of
Department of Health and Human Services Task Force on Alzheimer’s Disease.
Neurology 1984;3:939–44.
17 Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in
C9ORF72 is the cause of chromosome 9p21-Linked ALS-FTD. Neuron
2011;72:257–68.
18 Banca d’Italia. Indagine sui Bilanci delle Famiglie Italiane. Anno 2010
http://www.bancaditalia.it/statistiche/indcamp/bilfait
19 Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol
2012;11:1006–12.
20 Kaplan RF, Cohen RA, Moscufo N, et al. Demographic and biological inﬂuences on
cognitive reserve. J Clin Exp Neuropsychol 2009;31:868e76.
21 Borroni B, Premi E, Agosti C, et al. Revisiting brain reserve hypothesis in
frontotemporal dementia: evidence from a brain perfusion study. Dement Geriatr
Cogn Disord 2009;28:130–5.
22 Fairjones SE, Vuletich EJ, Pestell C, et al. Exploring the role of cognitive
reserve in early-onset dementia. Am J Alzheimers Dis Other Demen
2011;26:139–44.
23 Gordon PH, Delgadillo D, Piquard A, et al. The range and clinical impact of
cognitive impairment in French patients with ALS: a cross-sectional study of
neuropsychological test performance. Amyotroph Lateral Scler 2011;12:372–8.
24 Rippon G, Scarmeas N, Gordon PH, et al. An observational study of
cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol 2006;63:
345–52.
25 Schreiber H, Gaigalat T, Wiedemuth-Catrinescu U, et al. Cognitive function in
bulbar- and spinal-onset amyotrophic lateral sclerosis. A longitudinal study
in 52 patients. J Neurol 2005;252:772–81.
26 Hu WT, Seelaar H, Josephs KA, et al. Survival proﬁles of patients with
frontotemporal dementia and motor neuron disease. Arch Neurol
2009;66:1359–64.
27 Cistaro A, Valentini MC, Chiò A, et al. Brain hypermetabolism in amyotrophic lateral
sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol
Imaging 2012;39:251–9.
28 Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients
with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion:
a population-based cohort study. Lancet Neurol 2012;11:232–40.
29 Olney RK, Murphy J, Forshew D, et al. The effects of executive and behavioral
dysfunction on the course of ALS. Neurology 2005;65:1774–7.
30 Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic
indicator in patients with ALS without dementia. Neurology 2011;76:1263–9.
31 Elamin M, Bede P, Byrne S, et al. Cognitive changes predict functional decline in
ALS: a population-based longitudinal study. Neurology 2013;80:1590–7.
32 Kilani M, Micallef J, Soubrouillard C, et al. A longitudinal study of the evolution of
cognitive function and affective state in patients with amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:46–54.
6 Montuschi A, et al. J Neurol Neurosurg Psychiatry 2014;0:1–6. doi:10.1136/jnnp-2013-307223
Neurodegeneration
 group.bmj.com on September 24, 2014 - Published by jnnp.bmj.comDownloaded from 
doi: 10.1136/jnnp-2013-307223
 published online April 25, 2014J Neurol Neurosurg Psychiatry
 
Anna Montuschi, Barbara Iazzolino, Andrea Calvo, et al.
 
sclerosis: a population-based study in Italy
Cognitive correlates in amyotrophic lateral
 http://jnnp.bmj.com/content/early/2014/04/25/jnnp-2013-307223.full.html
Updated information and services can be found at: 
These include:
Data Supplement
 http://jnnp.bmj.com/content/suppl/2014/04/25/jnnp-2013-307223.DC1.html
"Supplementary Data"
References
 http://jnnp.bmj.com/content/early/2014/04/25/jnnp-2013-307223.full.html#ref-list-1
This article cites 27 articles, 3 of which can be accessed free at:
P<P Published online April 25, 2014 in advance of the print journal.
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
(DOIs) and date of initial publication. 
publication. Citations to Advance online articles must include the digital object identifier 
citable and establish publication priority; they are indexed by PubMed from initial
typeset, but have not not yet appeared in the paper journal. Advance online articles are 
Advance online articles have been peer reviewed, accepted for publication, edited and
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on September 24, 2014 - Published by jnnp.bmj.comDownloaded from 
Collections
Topic
 (299 articles)Psychiatry of old age   
 (1728 articles)Drugs: CNS (not psychiatric)   
 (891 articles)Dementia   
 (467 articles)Spinal cord   
 (1170 articles)Neuromuscular disease   
 (252 articles)Motor neurone disease   
 (1230 articles)Memory disorders (psychiatry)   
 
Articles on similar topics can be found in the following collections
Notes
(DOIs) and date of initial publication. 
publication. Citations to Advance online articles must include the digital object identifier 
citable and establish publication priority; they are indexed by PubMed from initial
typeset, but have not not yet appeared in the paper journal. Advance online articles are 
Advance online articles have been peer reviewed, accepted for publication, edited and
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on September 24, 2014 - Published by jnnp.bmj.comDownloaded from 
